


CLAIMS

What is claimed is:

1. A composition comprising one or more B-cell maturation antigen (BCMA)-targeting immuno-therapeutics and one or more compounds represented by the structure of Formula

5 (I):



and/or at least one salt thereof, wherein:

R₁ is -CH₂CF₃ or -CH₂CH₂CF₃;

R₂ is -CH₂CF₃, -CH₂CH₂CF₃, or -CH₂CH₂CH₂CF₃;

10 R₃ is H, -CH₃ or R_x;

R₄ is H or R_y;

R_x

is: -CH₂OC(O)CH(CH₃)NH₂, -CH₂OC(O)CH(NH₂)CH(CH₃)₂, -CH₂OC(O)CH((CH

(CH₃)₂)NHC(O)CH(NH₂)CH(CH₃)₂, -CH₂OC(O)CH₂--OP(O)(OH)₂,

-CH₂OC(O)CH₂C(CH₃)₂-, or -CH₂OC(O)--CH₂OP(O)(OH)₂;

15 R_y is: -SCH₂CH(NH₂)C(O)OH, -SCH₂CH(NH₂)C(O)OH₃,

or -SCH₂CH(NH₂)C(O)OC(CH₃)₃;

Ring A is phenyl or pyridinyl;

each R_a is independently F, Cl, -CN, -OCH₃, C₁₋₃ alkyl, -CH₂OH, -CF₃,


20 cyclopropyl, -OCH₃, -O(cyclopropyl) and/or -NHCH₂CH₂OCH₃;

each R_b is independently F, Cl, -CH₃, -CH₂OH, -CF₃, cyclopropyl, and/or -OCH₃;

y is zero, 1 or 2; and

z is 1 or 2.

2. The composition of claim 1, wherein said one or more compounds of Formula (I) are
- 25 represented by the structure of Formula (II):




wherein

R₃ is H or -CH₃; and

5 y is zero or 1.

3. The composition of claim 2, wherein said one or more compounds are represented by the structure of Formula (IV):



4. The composition of claim 1, wherein:

10 R₁ is -CH₂CH₂CF₃;

R₂ is -CH₂CH₂CF₃ or -CH₂CH₂CH₂CF₃; and

each R_a is independently Cl, C₁₋₃ alkyl, -CH₂OH, -CF₃, cyclopropyl, -OCH₃, and/or -O(cyclopropyl).


5. The composition of claim 4, wherein: Ring A is phenyl; and R₃ is H.

15 6. The composition of claim 4, wherein: R₂ is -CH₂CH₂CF₃; and Ring A is phenyl.

7. The composition of claim 4, wherein:

R₂ is -CH₂CH₂CF₃; Ring A is phenyl; R_a is C₁₋₃ alkyl or -CH₂OH; each R_b is independently F and/or Cl; and y is 1.

8. The composition of claim 4, wherein said one or more compounds are represented by the structure of Formula (V):
- 20




wherein:

R_3 is H or R_x .


9. The composition of claim 4, wherein said one or more compounds are selected from:
 - 5 (2R,3S)-N-((3S)-5-(3-fluorophenyl)-9-methyl-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (22); (2R,3S)-N-((3S)-5-(3-chlorophenyl)-9-ethyl-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (23); (2R,3S)-N-((3S)-5-(3-chlorophenyl)-9-isopropyl-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (24);
 - 10 (2R,3S)-N-(9-chloro-5-(3,4-dimethylphenyl)-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-3-(4,4,4-trifluorobutyl)-2-(3,3,3-trifluoropropyl)succinamide (25); (2R,3S)-N-(9-chloro-5-(3,5-dimethylphenyl)-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-3-(4,4,4-trifluorobutyl)-2-(3,3,3-trifluoropropyl)succinamide (26); (2R,3S)-N-((3S)-9-ethyl-5-(3-methylphenyl)-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (27);
 - 15 (2R,3S)-N-((3S)-5-(3-chlorophenyl)-9-methyl-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (28); (2R,3S)-N-((3S)-5-(3-chlorophenyl)-9-methyl-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-3-(4,4,4-trifluorobutyl)-2-(3,3,3-trifluoropropyl)succinamide (29); (2R,3S)-N-((3S)-5-(3-methylphenyl)-2-oxo-9-(trifluoromethyl)-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (30);
 - 20 (2R,3S)-N-((3S)-9-chloro-5-(3,5-dimethylphenyl)-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (31); (2R,3S)-N-((3S)-5-(3-methylphenyl)-2-oxo-9-(trifluoromethyl)-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-3-(4,4,4-trifluorobutyl)-2-(3,3,3-trifluoropropyl)succinamide (32); (2R,3S)-N-((3S)-9-isopropyl-5-(3-methylphenyl)-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (33);
 - 25 (2R,3S)-N-((3S)-9-(cyclopropyloxy)-5-(3-methylphenyl)-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-3-(4,4,4-trifluorobutyl)-2-(3,3,3-trifluoropropyl)succinamide (34); (2R,3S)-N-((3S)-9-(cyclopropyloxy)-5-(3-methylphenyl)-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (35); (2R,3S)-N-((3S)-9-

chloro-5-(3-methylphenyl)-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-3-(4,4,4-trifluorobutyl)-2-(3,3,3-trifluoropropyl) succinamide (36); (2R,3S)-N-((3S)-9-methyl-2-oxo-5-(3-(trifluoromethyl)phenyl)-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-3-(4,4,4-trifluorobutyl)-2-(3,3,3-trifluoropropyl) succinamide (37); (2R,3S)-N-((3S)-9-methyl-2-oxo-5-(3-(trifluoromethyl)phenyl)-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl) succinamide (38); (2R,3S)-N-((3S)-9-chloro-5-(2-methylphenyl)-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (39); (2R,3S)-N-((3S)-5-(4-fluorophenyl)-9-methyl-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (40); (2R,3S)-N-((3S)-9-chloro-5-(3-cyclopropylphenyl)-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (41); (2R,3S)-N-((3S)-5-(3-chlorophenyl)-9-methoxy-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (42); (2R,3S)-N-((3S)-5-(4-chlorophenyl)-9-methoxy-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (43); (2R,3S)-N-((3S)-9-chloro-5-(3-methylphenyl)-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (44); (2R,3S)-N-((3S)-5-(3-methylphenyl)-9-methoxy-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (45); (2R,3S)-N-((3S)-5-(4-(hydroxymethyl)phenyl)-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (46); (2R,3S)-N-((3S)-5-(2-methylphenyl)-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (47); (2R,3S)-N-((3S)-5-(3-methylphenyl)-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (48); (2R,3S)-N-((3S)-9-methoxy-2-oxo-5-(5-(trifluoromethyl)-2-pyridinyl)-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (49); (2R,3S)-N-((3S)-5-(5-chloro-2-pyridinyl)-9-methoxy-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (50); (2R,3S)-N-((3S)-5-(4-methoxyphenyl)-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (51); (2R,3S)-N-((3S)-5-(4-methylphenyl)-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (52); (2R,3S)-N-((3S)-5-(3-fluorophenyl)-9-(hydroxymethyl)-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (53); ((3S)-3-(((2R,3S)-3-carbamoyl-6,6,6-trifluoro-2-(3,3,3-trifluoropropyl)hexanoyl)amino)-5-(3-fluorophenyl)-9-methyl-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-1-yl)methyl L-valinate (54); ((3S)-3-(((2R,3S)-3-carbamoyl-6,6,6-trifluoro-2-(3,3,3-trifluoropropyl)hexanoyl)amino)-5-(3-fluorophenyl)-9-methyl-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-1-yl)methyl L-alaninate (55); S-(((2S,3R)-6,6,6-trifluoro-3-(((3S)-5-(3-fluorophenyl)-9-methyl-2-oxo-2,3-dihydro-

- 1H-1,4-benzodiazepin-3-yl)carbamoyl)-2-(3,3,3-trifluoropropyl)hexanoyl)amino)-L-cysteine (56); *tert*-butyl S-(((2S,3R)-6,6,6-trifluoro-3-(((3S)-5-(3-fluorophenyl)-9-methyl-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)carbamoyl)-2-(3,3,3-trifluoropropyl)hexanoyl)amino)-L-cysteinate (57); methyl S-(((2S,3R)-6,6,6-trifluoro-3-(((3S)-5-(3-fluorophenyl)-9-methyl-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)carbamoyl)-2-(3,3,3-trifluoropropyl)hexanoyl)amino)-L-cysteinate (58); ((3S)-3-(((2R,3S)-3-carbamoyl-6,6,6-trifluoro-2-(3,3,3-trifluoropropyl)hexanoyl)amino)-5-(3-fluorophenyl)-9-methyl-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-1-yl)methyl (4-(phosphonoxy)phenyl)acetate (59); ((3S)-3-(((2R,3S)-3-carbamoyl-6,6,6-trifluoro-2-(3,3,3-trifluoropropyl)hexanoyl)amino)-5-(3-fluorophenyl)-9-methyl-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-1-yl)methyl L-valyl-L-valinate (60); and salts thereof.
10. The composition of claim 8, wherein said compound comprises:



11. The composition of any one of claims 1-10, wherein said BCMA-targeting immunotherapeutic comprises chimeric antigen receptor T (CAR-T) cells.
12. The composition of any one of claims 1-10, wherein said BCMA-targeting immunotherapeutic comprises an antibody drug conjugate, bispecific antibody, tri-specific antibody, trifunctional antibody, chemically linked Fab or a bi-specific T-cell engager (BiTE).
13. A method of treating, suppressing or inhibiting a B-cell maturation antigen (BCMA)-related disorder or a disease associated with BCMA expression in a subject comprising the step of administering to said subject a first composition comprising one or more BCMA-targeting immuno-therapeutics and a second composition comprising one or more compounds represented by the structure of Formula (I):



and/or at least one salt thereof, wherein:

R₁ is -CH₂CF₃ or -CH₂CH₂CF₃;

R₂ is -CH₂CF₃, -CH₂CH₂CF₃, or -CH₂CH₂CH₂CF₃;


R₃ is H, -CH₃ or R_x;

5 R₄ is H or R_y;

R_x

is: -CH₂OC(O)CH(CH₃)NH₂, -CH₂OC(O)CH(NH₂)CH(CH₃)₂, -CH₂OC(O)CH((CH

(CH₃)₂)NHC(O)CH(NH₂)CH(CH₃)₂, -CH₂OC(O)CH₂--OP(O)(OH)₂,
,

-CH₂OC(O)CH₂C(CH₃)₂--CH₃,
(HO)₂(O)PO, or -CH₂OC(O)--CH₂OP(O)(OH)₂;

10 R_y is: -SCH₂CH(NH₂)C(O)OH, -SCH₂CH(NH₂)C(O)OH₃,

or -SCH₂CH(NH₂)C(O)OC(CH₃)₃;

Ring A is phenyl or pyridinyl;

each R_a is independently F, Cl, -CN, -OCH₃, C₁₋₃ alkyl, -CH₂OH, -CF₃,

cyclopropyl, -OCH₃, -O(cyclopropyl) and/or -NHCH₂CH₂OCH₃;


15 each R_b is independently F, Cl, -CH₃, -CH₂OH, -CF₃, cyclopropyl, and/or -OCH₃;

y is zero, 1 or 2; and

z is 1 or 2.

14. The method of claim 13, wherein said BCMA-related disorder comprises a proliferative disease.

20 15. A method of treating, suppressing or inhibiting a proliferative disease in a subject comprising the step of administering to said subject a first composition comprising one or more B-cell maturation antigen (BCMA)-targeting immuno-therapeutics and a second composition comprising one or more compounds represented by the structure of Formula (I):



25 and/or at least one salt thereof, wherein:

R₁ is -CH₂CF₃ or -CH₂CH₂CF₃;


R₂ is -CH₂CF₃, -CH₂CH₂CF₃, or -CH₂CH₂CH₂CF₃;

R_3 is H, $-CH_3$ or R_x ;

R_4 is H or R_y ;

R_x

is: $-CH_2OC(O)CH(CH_3)NH_2$, $-CH_2OC(O)CH(NH_2)CH(CH_3)_2$, $-CH_2OC(O)CH((CH$



R_y is: $-SCH_2CH(NH_2)C(O)OH$, $-SCH_2CH(NH_2)C(O)OH_3$,

or $-SCH_2CH(NH_2)C(O)OC(CH_3)_3$;

Ring A is phenyl or pyridinyl;

10 each R_a is independently F, Cl, $-CN$, $-OCH_3$, C_{1-3} alkyl, $-CH_2OH$, $-CF_3$,

cyclopropyl, $-OCH_3$, $-O(cyclopropyl)$ and/or $-NHCH_2CH_2OCH_3$;

each R_b is independently F, Cl, $-CH_3$, $-CH_2OH$, $-CF_3$, cyclopropyl, and/or $-OCH_3$;


y is zero, 1 or 2; and

z is 1 or 2.

15 16. The method of any one of claims 14-15, wherein said proliferative disease is a pre-cancerous condition or a benign proliferative disorder.

17. The method of any one of claims 14-15, wherein said proliferative disease is a cancer.

18. A method of improving the efficacy of an anti-B-cell maturation antigen (BCMA) therapy in a subject comprising the step of administering to said subject a first composition comprising
20 one or more BCMA-targeting immuno-therapeutics and a second composition comprising one or more compounds represented by the structure of Formula (I):



and/or at least one salt thereof, wherein:

R_1 is $-CH_2CF_3$ or $-CH_2CH_2CF_3$;


25 R_2 is $-CH_2CF_3$, $-CH_2CH_2CF_3$, or $-CH_2CH_2CH_2CF_3$;

R_3 is H, $-CH_3$ or R_x ;

R_4 is H or R_y ;

R_x


is: $-\text{CH}_2\text{OC}(\text{O})\text{CH}(\text{CH}_3)\text{NH}_2$, $-\text{CH}_2\text{OC}(\text{O})\text{CH}(\text{NH}_2)\text{CH}(\text{CH}_3)_2$, $-\text{CH}_2\text{OC}(\text{O})\text{CH}((\text{CH}_3)_2\text{NHC}(\text{O})\text{CH}(\text{NH}_2)\text{CH}(\text{CH}_3)_2)$, $-\text{CH}_2\text{OC}(\text{O})\text{CH}_2$ -- $\text{OP}(\text{O})(\text{OH})_2$,



- 5 R_y is: $-\text{SCH}_2\text{CH}(\text{NH}_2)\text{C}(\text{O})\text{OH}$, $-\text{SCH}_2\text{CH}(\text{NH}_2)\text{C}(\text{O})\text{OH}_3$,
or $-\text{SCH}_2\text{CH}(\text{NH}_2)\text{C}(\text{O})\text{OC}(\text{CH}_3)_3$;
Ring A is phenyl or pyridinyl;
each R_a is independently F, Cl, -CN, -OCH₃, C₁₋₃ alkyl, -CH₂OH, -CF₃,
cyclopropyl, -OCH₃, -O(cyclopropyl) and/or -NHCH₂CH₂OCH₃;
10 each R_b is independently F, Cl, -CH₃, -CH₂OH, -CF₃, cyclopropyl, and/or -OCH₃;
y is zero, 1 or 2; and
z is 1 or 2.

19. The method of claim 18, wherein said anti-BCMA therapy comprises an anti-cancer therapy.
20. The method of any one of claims 13-19, wherein said BCMA-targeting immunotherapeutic
15 comprises chimeric antigen receptor T (CAR-T) cells.
21. The method of any one of claims 13-19, wherein said BCMA-targeting immunotherapeutic
comprises an antibody drug conjugate, bispecific antibody, tri-specific antibody, trifunctional
antibody, chemically linked Fab or a bi-specific T-cell engager (BiTE).
22. The method of any one of claims 13-21, wherein said first composition and/or said second
20 composition is intravenously administered to said subject.
23. The method of any one of claims 13-21, wherein said first composition and/or said second
composition is orally administered to said subject.
24. The method of any one of claims 13-21, wherein said first composition and said second
composition are administered together.
25 25. The method of any one of claims 13-21, wherein said first composition and said second
composition are administered at separate sites or at separate times.
26. The method of any one of claims 13-21, wherein said composition comprising Formula (I) is
administered prior to and then again subsequent to the administration of said composition
comprising said one or more B-cell maturation antigen (BCMA)-targeting immuno-
30 therapeutics.

27. A method of decreasing B-cell maturation antigen (BCMA) shedding from a cancer cell in a subject comprising the step of administering to said subject a composition comprising one or more compounds represented by the structure of Formula (I):



5 and/or at least one salt thereof, wherein:

R_1 is $-\text{CH}_2\text{CF}_3$ or $-\text{CH}_2\text{CH}_2\text{CF}_3$;

R_2 is $-\text{CH}_2\text{CF}_3$, $-\text{CH}_2\text{CH}_2\text{CF}_3$, or $-\text{CH}_2\text{CH}_2\text{CH}_2\text{CF}_3$;


R_3 is H, $-\text{CH}_3$ or R_x ;

R_4 is H or R_y ;

10 R_x

is: $-\text{CH}_2\text{OC}(\text{O})\text{CH}(\text{CH}_3)\text{NH}_2$, $-\text{CH}_2\text{OC}(\text{O})\text{CH}(\text{NH}_2)\text{CH}(\text{CH}_3)_2$, $-\text{CH}_2\text{OC}(\text{O})\text{CH}((\text{CH}$

$(\text{CH}_3)_2)\text{NHC}(\text{O})\text{CH}(\text{NH}_2)\text{CH}(\text{CH}_3)_2$, $-\text{CH}_2\text{OC}(\text{O})\text{CH}_2$ -- $\text{OP}(\text{O})(\text{OH})_2$,

$-\text{CH}_2\text{OC}(\text{O})\text{CH}_2\text{C}(\text{CH}_3)_2$ -, or $-\text{CH}_2\text{OC}(\text{O})$ -- $\text{CH}_2\text{OP}(\text{O})(\text{OH})_2$;

R_y is: $-\text{SCH}_2\text{CH}(\text{NH}_2)\text{C}(\text{O})\text{OH}$, $-\text{SCH}_2\text{CH}(\text{NH}_2)\text{C}(\text{O})\text{OH}_3$,

15 or $-\text{SCH}_2\text{CH}(\text{NH}_2)\text{C}(\text{O})\text{OC}(\text{CH}_3)_3$;

Ring A is phenyl or pyridinyl;

each R_a is independently F, Cl, $-\text{CN}$, $-\text{OCH}_3$, C_{1-3} alkyl, $-\text{CH}_2\text{OH}$, $-\text{CF}_3$,

cyclopropyl, $-\text{OCH}_3$, $-\text{O}(\text{cyclopropyl})$ and/or $-\text{NHCH}_2\text{CH}_2\text{OCH}_3$;

each R_b is independently F, Cl, $-\text{CH}_3$, $-\text{CH}_2\text{OH}$, $-\text{CF}_3$, cyclopropyl, and/or $-\text{OCH}_3$;

20 y is zero, 1 or 2; and


z is 1 or 2.

28. The method of claim 27, wherein said composition is administered intravenously or orally to said subject.

29. The method of any one of claims 17 and 19-28, wherein said cancer comprises multiple myeloma.


30. The method of any one of claims 17 and 19-28, wherein said cancer comprises leukemia.

31. The method of claim 30, wherein said leukemia comprises T-cell acute lymphoblastic leukemia (T-ALL).
32. The method of any one of claims 17 and 19-28, wherein said cancer comprises lymphoma.
33. The method of any one of claims 17 and 19-28, wherein said cancer comprises a solid tumor.
34. The method of any one of claims 13-33, wherein said one or more compounds of Formula (I) are represented by the structure of Formula (II):



wherein

35. The method of claim 34, wherein said one or more compounds is represented by the structure of Formula (IV):




36. The method of claim 34, wherein:
- R_1 is $-\text{CH}_2\text{CH}_2\text{CF}_3$;
 - R_2 is $-\text{CH}_2\text{CH}_2\text{CF}_3$ or $-\text{CH}_2\text{CH}_2\text{CH}_2\text{CF}_3$; and
 - each R_a is independently Cl, C_{1-3} alkyl, $-\text{CH}_2\text{OH}$, $-\text{CF}_3$, cyclopropyl, $-\text{OCH}_3$, and/or $-\text{O}(\text{cyclopropyl})$.
37. The method of claim 36, wherein:
- Ring A is phenyl; and R_3 is H.
38. The method of claim 36, wherein:
- R_2 is $-\text{CH}_2\text{CH}_2\text{CF}_3$; and Ring A is phenyl.

39. The method of claim 36, wherein:

R_2 is $-\text{CH}_2\text{CH}_2\text{CF}_3$; Ring A is phenyl; R_a is C_{1-3} alkyl or $-\text{CH}_2\text{OH}$; each R_b is independently F and/or Cl; and y is 1.

40. The method of claim 36, wherein said one or more compounds is represented by the

5 structure of Formula (V):



wherein R_3 is H or R_x .

41. The method of claim 36, wherein said one or more compounds are selected from:

- (2R,3S)-N-((3S)-5-(3-fluorophenyl)-9-methyl-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (22); (2R,3S)-N-((3S)-5-(3-chlorophenyl)-9-ethyl-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (23); (2R,3S)-N-((3S)-5-(3-chlorophenyl)-9-isopropyl-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (24); (2R,3S)-N-(9-chloro-5-(3,4-dimethylphenyl)-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-3-(4,4,4-trifluorobutyl)-2-(3,3,3-trifluoropropyl)succinamide (25); (2R,3S)-N-(9-chloro-5-(3,5-dimethylphenyl)-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-3-(4,4,4-trifluorobutyl)-2-(3,3,3-trifluoropropyl)succinamide (26); (2R,3S)-N-((3S)-9-ethyl-5-(3-methylphenyl)-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (27); (2R,3S)-N-((3S)-5-(3-chlorophenyl)-9-methyl-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (28); (2R,3S)-N-((3S)-5-(3-chlorophenyl)-9-ethyl-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-3-(4,4,4-trifluorobutyl)-2-(3,3,3-trifluoropropyl)succinamide (29); (2R,3S)-N-((3S)-5-(3-methylphenyl)-2-oxo-9-(trifluoromethyl)-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (30); (2R,3S)-N-((3S)-9-chloro-5-(3,5-dimethylphenyl)-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (31); (2R,3S)-N-((3S)-5-(3-methylphenyl)-2-oxo-9-(trifluoromethyl)-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-3-(4,4,4-trifluorobutyl)-2-(3,3,3-trifluoropropyl)succinamide (32); (2R,3S)-N-((3S)-9-isopropyl-5-(3-methylphenyl)-2-oxo-2,3-dihydro-1H-1,4-

benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (33); (2R,3S)-N-((3S)-9-(cyclopropyloxy)-5-(3-methylphenyl)-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-3-(4,4,4-trifluorobutyl)-2-(3,3,3-trifluoropropyl)succinamide (34); (2R,3S)-N-((3S)-9-(cyclopropyloxy)-5-(3-methylphenyl)-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (35); (2R,3S)-N-((3S)-9-chloro-5-(3-methylphenyl)-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-3-(4,4,4-trifluorobutyl)-2-(3,3,3-trifluoropropyl)succinamide (36); (2R,3S)-N-((3S)-9-methyl-2-oxo-5-(3-(trifluoromethyl)phenyl)-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-3-(4,4,4-trifluorobutyl)-2-(3,3,3-trifluoropropyl)succinamide (37); (2R,3S)-N-((3S)-9-methyl-2-oxo-5-(3-(trifluoromethyl)phenyl)-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (38); (2R,3S)-N-((3S)-9-chloro-5-(2-methylphenyl)-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (39); (2R,3S)-N-((3S)-5-(4-fluorophenyl)-9-methyl-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (40); (2R,3S)-N-((3S)-9-chloro-5-(3-cyclopropylphenyl)-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (41); (2R,3S)-N-((3S)-5-(3-chlorophenyl)-9-methoxy-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (42); (2R,3S)-N-((3S)-5-(4-chlorophenyl)-9-methoxy-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (43); (2R,3S)-N-((3S)-9-chloro-5-(3-methylphenyl)-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (44); (2R,3S)-N-((3S)-5-(3-methylphenyl)-9-methoxy-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (45); (2R,3S)-N-((3S)-5-(4-(hydroxymethyl)phenyl)-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (46); (2R,3S)-N-((3S)-5-(2-methylphenyl)-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (47); (2R,3S)-N-((3S)-5-(3-methylphenyl)-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (48); (2R,3S)-N-((3S)-9-methoxy-2-oxo-5-(5-(trifluoromethyl)-2-pyridinyl)-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (49); (2R,3S)-N-((3S)-5-(5-chloro-2-pyridinyl)-9-methoxy-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (50); (2R,3S)-N-((3S)-5-(4-methoxyphenyl)-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (51); (2R,3S)-N-((3S)-5-(4-methylphenyl)-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (52); (2R,3S)-N-((3S)-5-(3-fluorophenyl)-9-

- (hydroxymethyl)-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide (53); ((3S)-3-(((2R,3S)-3-carbamoyl-6,6,6-trifluoro-2-(3,3,3-trifluoropropyl)hexanoyl)amino)-5-(3-fluorophenyl)-9-methyl-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-1-yl)methyl L-valinate (54); ((3S)-3-(((2R,3S)-3-carbamoyl-6,6,6-trifluoro-2-(3,3,3-trifluoropropyl)hexanoyl)amino)-5-(3-fluorophenyl)-9-methyl-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-1-yl)methyl L-alaninate (55); S-(((2S,3R)-6,6,6-trifluoro-3-(((3S)-5-(3-fluorophenyl)-9-methyl-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)carbamoyl)-2-(3,3,3-trifluoropropyl)hexanoyl)amino)-L-cysteine (56); *tert*-butyl S-(((2S,3R)-6,6,6-trifluoro-3-(((3S)-5-(3-fluorophenyl)-9-methyl-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)carbamoyl)-2-(3,3,3-trifluoropropyl)hexanoyl)amino)-L-cysteinate (57); methyl S-(((2S,3R)-6,6,6-trifluoro-3-(((3S)-5-(3-fluorophenyl)-9-methyl-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)carbamoyl)-2-(3,3,3-trifluoropropyl)hexanoyl)amino)-L-cysteinate (58); ((3S)-3-(((2R,3S)-3-carbamoyl-6,6,6-trifluoro-2-(3,3,3-trifluoropropyl)hexanoyl)amino)-5-(3-fluorophenyl)-9-methyl-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-1-yl)methyl (4-(phosphonooxy)phenyl)acetate (59); ((3S)-3-(((2R,3S)-3-carbamoyl-6,6,6-trifluoro-2-(3,3,3-trifluoropropyl)hexanoyl)amino)-5-(3-fluorophenyl)-9-methyl-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-1-yl)methyl L-valyl-L-valinate (60); and salts thereof.

42. The method of claim 36, wherein said compound comprises:

